Medical Oncology 🏥 Hospital General Universitario Gregorio Marañón ⎪@myESMO Faculty 🫁 ⎪#endlungcancer #lcsm
Joined October 2013
- Tweets 24,562
- Following 4,424
- Followers 12,157
- Likes 25,028
Photos and videos
Pinned Tweet
9 Dec 2024
🎉 Online first: After positive press release of IMforte trial, our timely published review of the MoA of #lurbinectedin and its implications for combinational therapies in #SCLC, including immunotherapy. #LCSM 🫁
Check it out here 👉aacrjournals.org/mct/article…
5
20
64
9,479
Dr. Antonio Calles 🫁🚭 retweeted
Jun 11
📣 #ESMO26: A place to transform the way you treat cancer. Discover innovations and collaborate with experts to advance your practice. Register today!
⏰ Early registration deadline: 22 July 2026
🔗 ow.ly/B5Ky50Z69tp
#esmomeetings
1
3
8
1,676
Dr. Antonio Calles 🫁🚭 retweeted
🔥🚨1/2 @OncoAlert Hot off the press.
⭐️My co-authors & I are excited & proud to share this, JUST PUBLISHED, #Manuscript in the 2026 #ASCOEdBook in conjunction with #EducationSession Presentation at #ASCO26 @ASCO👇🏻
❇️“#Updates in #SmallCell #LungCancer-NO LONGER TOO SMAL to Ignore. A #Review of Recent #Therapeutic #Advances.”
👇🏻
ascopubs.org/doi/10.1200/EDB…
5
30
83
5,163
Dr. Antonio Calles 🫁🚭 retweeted
Jun 3
Please use the KRAS Kickers trial finder to help your patients...
Four KRAS G12D trials recruiting in Spain
Three more pan-RAS or pan-KRAS trials
KRAShub.org
ASCO26 goal "The Science and Practice of Translation: Improving Cancer Outcomes Worldwide."
From flight to bedside!
@ASCO
✈️ Recién aterrizado de Chicago, directo al hospital 🏥
💊 Espero que tras las esperanzadores noticias de darasonxasib en cáncer de páncreas aumente el interés de los pacientes en participar en ensayos clínicos con inhibidor de KRAS.
Difundámoslo!!! #endlungcancer
#ASCO25 #LCSM @AEACaP
4
3
938
✈️ Recién aterrizado de Chicago, directo al hospital 🏥
💊 Espero que tras las esperanzadores noticias de darasonxasib en cáncer de páncreas aumente el interés de los pacientes en participar en ensayos clínicos con inhibidor de KRAS.
Difundámoslo!!! #endlungcancer
#ASCO25 #LCSM @AEACaP
3
11
34
2,503
Dr. Antonio Calles 🫁🚭 retweeted
Phase Ib results from the phase Ib/II study of [Lu]Lu-DOTA-TATE in combination with standard of care as a first-line treatment for pts with ES-SCLC.
☢️ Feasible but challenging combination. Hard to understand the contribution of Lu-DOTA-TATE in terms of efficacy. Ongoing phase II study no longer recruiting patients.
#ASCO25 #SCLC #LCSM
9
15
2,070
Dr. Antonio Calles 🫁🚭 retweeted
May 30
FLAME; IIT F vs F2 …. Individualised escalation at 3w osi monotherapy if persistence ctDNA positivity; PFS 23.1m HR 0.54; OS NR HR 0.62; #ASCO26
2
4
607
💊 First-in-human trial of BH-30643, a novel macrocyclic, non-covalent, mutant-selective OMNI-EGFR inhibitor:
Activity in C797S both with or without
T790M. High plasma exposures, potencial CNS activity, and favorable safety in heavily pretreated EGFR-mut NSCLC. Expansion cohorts ongoing.
#ASCO26 #LCSM
15
33
2,566
🇪🇺 Yesterday, the European Commission approved lurbinectedin and tarlatamab for the treatment of patients with SCLC. This marks a major milestone for patients across Europe, providing access to the first two drugs in decades to demonstrate a survival benefit in this setting after years of setbacks and dozens of negative phase III trials in a particularly challenging disease. Kudos to everyone who helped make this happen.
wwwext.amgen.com/newsroom/pr…
🚨 Breaking News 🚨
PharmaMar ha recibido la aprobación de la @EU_Commission para la combinación de nuestra terapia, en combinación con inmunoterapia, para cáncer de pulmón de célula pequeña en estadio avanzado.
📌La aprobación llega tras la opinión positiva de la @EMA_News - Agencia Europea del Medicamento, y se basa en los resultados del ensayo de fase 3 IMforte.
📌En Europa se diagnostican alrededor de 62.000 nuevos casos anuales de cáncer de pulmón de célula pequeña, un tipo agresivo de cáncer de pulmón, caracterizado por un crecimiento rápido y una diseminación temprana.
Más información en: pharmamar.com/es/la-comision…
Información dirigida hacia #medios e #inversores.
1
7
22
2,923
Dr. Antonio Calles 🫁🚭 retweeted
What a happy coincidence!
While presenting intracranial efficacy data from DeLLphi-304 in #ASCO26, #Tarlatamab was officially approved in EU!!
✅ In ITT: CNS mPFS NR vs 7.8 m, HR=0.54
✅ In BM per mRANO: CNS mPFS 6.5 vs 4.2m, HR=0.4
✅ mOS=13.9 vs 6.8, HR=0.51, independent of baseline BM!
A new SoC, hope that all #SCLC patients will soon have access!!
#some #LCSM @OncoAlert @OncBrothers
@OncLive @PortalOnconews @SclcSMASHERS
@myESMO @ASCO @IASCL @PeerView
4
37
84
6,863
Dr. Antonio Calles 🫁🚭 retweeted
💥 Mic drop
📉 7 year-PFS not reached for lorlatinib in the CROWN trial in ALK lung cancer.
🧠 Completely transformative for CNS disease. #LCSM #ASCO26 @alk_fusion
1
13
42
2,722
Dr. Antonio Calles 🫁🚭 retweeted
💊 Practice changing LIBRETTO-432 trial:
Adjuvant selpercatinib HR 0.13 for DFS in stage II-III RET NSCLC after adjuvant chemotherapy.
‼️ Comprehensive biomarker testing is mandatory
⚠️Note: it requiered n=3149 biomarker negative test to enroll 151 pts. So never give up!!! #ASCO26 #LCSM
10
17
1,497
Dr. Antonio Calles 🫁🚭 retweeted
🔥🚨@OncoAlert Hot off the press.
‼️‼️No better way to conclude exciting #LungCancer Data from #ASCO26, than
a GREAT @Nature #Paper.
📣Just published @Nature in conjunction with presentation @ASCO #ASCO26.
⭐️ Results of phase 1 trial of:
❇️#ABBV706 (#SEZ6 #ADC) in patients with advanced #SmallCell #LungCancer (#SCLC).
👇🏻
nature.com/articles/s41591-0…
🔥🚨@OncoAlert Hot off the press.
Just presented @ASCO #ASCO26 by Dr.
@LaurenByersMD
⭐️ Results of phase 1 trial of:
❇️#ABBV706 (#SEZ6 #ADC) as #monotherapy & in combination with #Budigalimab (anti-PD1 Ab) in patients with relapsed/refractory #SmallCell #LungCancer (#SCLC).
For pts on Monotherapy:
✅#ORR: 52% (82% at 1.8 mg/kg in 2L)
✅#mOS: 11.3 m (14.3 at 1.8 mg/kg in 2L)
For pts on combination:
✅#ORR: 55%
✅#mOS: not reached
4
13
30
2,316
Dr. Antonio Calles 🫁🚭 retweeted
☢️ Concurrent thoracic radiotherapy chemotherapy durvalumab phase III trial in stage IV SCLC stopped early due to excess of deaths in the radiotherapy arm.
Not improvement in ORR, PFS, or OS but added toxicity to standard CASPIAN.
A definitively NOT TO DO. #ASCO26 #LCSM
1
6
11
2,030
Tarlatamab continues to impress the oncology community with the CNS activity in relapsed ES-SCLC presented today.
🧠 Controlling not only previously treated brain metastases at baseline but also preventing them from appearing, while maintaining a better tox profile than chemotherapy, with the exception of disgeusia 👅 and increased ICANS
#ASCO26 #LCSM
1
9
13
770